Pulmonary Cell News Volume 2.37 | Sep 19 2013

Protective Effect of Hypercapnic Acidosis in Ischemia-Reperfusion Lung Injury Is Attributable to Upregulation of Heme Oxygenase-1
Researchers investigated whether heme oxygenase-1 (HO-1) contributes to the protective effects of hypercapnic acidosis (HCA) in ischemia-reperfusion-induced lung injury. HO-1 siRNA significantly reversed HCA-mediated inhibition of NF-κB signaling in A549 cells subjected to hypoxia-reoxygenation. [PLoS One] Full Article

EGF-Induced Bronchial Epithelial Cells Drive Neutrophil Chemotactic and Anti-Apoptotic Activity in Asthma
Primary bronchial epithelial cells from healthy subjects, mild asthmatics and moderate-to-severe asthmatics were stimulated with epidermal growth factor (EGF), a model that mimics a repairing epithelium. EGF induced the epithelium to produce soluble mediators with neutrophil chemotactic and pro-survival activities which were related to the clinical severity of asthma. [PLoS One] Full Article

Cycloheximide and Lipopolysaccharide Downregulate αENaC mRNA via Different Mechanisms in Alveolar Epithelial Cells
The regulatory mechanisms of α epithelial Na⁺ channel (αENaC) mRNA expression by cycloheximide and lipopolysaccharide from Pseudomonas aeruginosa were studied. Both agents decreased αENaC mRNA expression to 50% of control values after 4 hours. [Am J Physiol Lung Cell Mol Physiol] Abstract

LUNG CANCER

Co-Assessment of Cell Cycle and Micronucleus Frequencies Demonstrates the Influence of Serum on the In Vitro Genotoxic Response to Amorphous Monodisperse Silica Nanoparticles of Varying Sizes
Researchers investigated the influence of serum on the induction of micronuclei by nanoparticles of different sizes. Therefore they used A549 human lung carcinoma cells and amorphous monodisperse silica nanoparticles as models. [Nanotoxicology] Abstract

p190A RhoGAP Is Involved in EGFR Pathways and Promotes Proliferation, Invasion and Migration in Lung Adenocarcinoma Cells
Researchers documented inhibition of phosphorylation of p190-A RhoGAP (p190) by epidermal growth factor receptor (EGFR) -tyrosine kinase inhibitors treatment in lung adenocarcinoma cell lines. Small interfering RNA-mediated knockdown of p190 leads lung adenocarcinoma cells to growth suppression and to inhibition of invasion/migration through inducing cell cycle arrest but not apoptosis. [Int J Oncol] Abstract

SIRT3 Regulates Cell Proliferation and Apoptosis Related to Energy Metabolism in Non-Small Cell Lung Cancer Cells through Deacetylation of NMNAT2
The interaction on growth, proliferation, apoptosis of non-small cell lung carcinoma (NSCLC) cell lines, and energy metabolism related to SIRT3 were investigated. Low expression of SIRT3 significantly inhibited mitotic entry, growth and proliferation of NSCLC cell lines and promoted apoptosis, which was related to energy metabolism involving in the interaction between SIRT3 and NMNAT2. [Int J Oncol] Abstract | Full Article

Targeting SHP2 for EGFR Inhibitor Resistant Non-Small Cell Lung Carcinoma
Researchers showed that Src homology 2-domain containing protein tyrosine phosphatase-2 (SHP2) is required for EGF-stimulated ERK1/2 phosphorylation and proliferation in epidermal growth factor receptor (EGFR) inhibitor resistant non-small cell lung cancer cell line H1975, which harbors the EGFR T790M/L858R double-mutant. [Biochem Biophys Res Commun] Abstract

The Antiproliferative Effect of Moringa oleifera Crude Aqueous Leaf Extract on Cancerous Human Alveolar Epithelial Cells
Scientists investigated the antiproliferative effect of Moringa oleifera leaf extract (MOE) in cancerous A549 lung cells. A significant increase in reactive oxygen species with a concomitant decrease in intracellular glutathione levels in MOE treated A549 cells was observed. [BMC Complement Altern Med]
Abstract | Full Article

Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.

Celtaxsys Announces Successful Completion of Phase I Clinical Trial for Development of CTX-4430
Atlanta-based pharmaceutical discovery and development company, Celtaxsys, Inc., announced the achievement of a significant clinical milestone for its lead clinical stage drug candidate, CTX-4430, for treatment of Cystic Fibrosis lung disease. [Celtaxsys, Inc.] Press Release

Ventana Receives Approval from China’s FDA for First Fully Automated IHC Companion Diagnostic Identifying ALK Protein Expression in Lung Cancer Patients
Ventana Medical Systems, Inc. announced the approval of the VENTANA ALK immunohistochemistry (IHC) assay by the Chinese Food and Drug Administration (CFDA) as a companion diagnostic to aid in the identification of patients for Pfizer’s CFDA-approved oncology product XALKORI^®. [Ventana Medical Systems, Inc.] Press Release

From our sponsor: Free human hematopoietic progenitors wallchart. Request your copy.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the pulmonary cell community.

NEW Postdoctoral Fellow – Lung Research (Brigham & Women’s Hospital – Harvard Medical School)

Postdoctoral Research Position – Pathogenesis of Pulmonary Fibrosis (Biomedical Sciences Research Center)

Postdoctoral Research Candidate – Chronic Lung Diseases (European Respiratory Society / Marie Curie)

Postdoctoral Research Position – Molecular and Cellular Mechanism of Pulmonary Vascular Inflammation and Dysfunction (University of Oklahoma Health Sciences Center)

Postdoctoral Position – Cardiopulmonary Molecular Biology (Hannover Medical School)

Postdoctoral Researcher – Respiratory Diseases Research (Boehringer Ingelheim Pharma GmbH & Co. KG)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Postdoctoral Associate – Lung Cancer (Yale Cancer Center)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.